Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.45 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3583014 | 1.00 | IDO1 (0.53) | IDO1TSHRBLMHTTALDH1A1 | |
| SCHEMBL59026 | 1.00 | IDO1 (0.53) | IDO1TSHRBLMHTTALDH1A1 | |
| SCHEMBL29449692 | 1.00 | IDO1 (0.53) | IDO1TSHRBLMHTTALDH1A1 | |
| Benzene SCHEMBL28873131 | 0.98 | IDO1 (0.52) | IDO1TSHRBLMHTTALDH1A1 | |
| Hydrochloric Acid SCHEMBL22770167 | 0.98 | IDO1 (0.55) | IDO1TSHRBLMHTTALDH1A1 | |
| Bromide SCHEMBL9033434 | 0.98 | IDO1 (0.52) | IDO1TSHRBLMHTTALDH1A1 | |
| Water SCHEMBL28334394 | 0.98 | IDO1 (0.52) | IDO1TSHRBLMHTTALDH1A1 | |
| SCHEMBL29622997 | 0.94 | TSHR (0.48) | IDO1TSHRBLMHTTEPHX1 | |
| SCHEMBL29182252 | 0.94 | TSHR (0.48) | IDO1TSHRBLMHTTEPHX1 | |
| SCHEMBL2192515 | 0.94 | TSHR (0.48) | IDO1TSHRBLMHTTEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6589777-B1 | Use to prepare enantiomerically pure precursor material for sertraline synthesis - \"(4S) tetralone\" or 4-(3,4-dichloro-phenyl)-3,4-dihydro-1(2H)-naphthalenone and for subsequent use in preparation of antidepressant and anorectic agents | PFIZER INC. | 2003-07-08 | — | — | US | claimed |
| CN-111320651-B | Chiral amino-pyridine-phosphine tridentate ligand, manganese complex, preparation method and application thereof | 中国科学院上海有机化学研究所 | 2023-01-17 | — | — | CN | disclosed |
| CN-110467609-B | Aggregation-induced emission material with circular polarization luminescence and thermal activation delayed fluorescence emission simultaneously, and preparation method and application thereof | 华南师范大学 | 2023-01-10 | — | — | CN | disclosed |
| CN-110003084-B | Organic circular polarization luminescent material with both mechanoluminescence and aggregation-induced luminescence characteristics, and preparation method and application thereof | 华南师范大学 | 2022-08-02 | — | — | CN | disclosed |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2021-11-30 | — | — | US | disclosed |
| EP-2706999-B1 | SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2019-08-28 | — | — | EP | disclosed |
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2019-06-27 | — | — | US | disclosed |
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2019-06-27 | — | — | US | disclosed |
| WO-2018026371-A1 | DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2018-02-08 | — | — | WO | disclosed |
| US-6005133-A | STEREOSELECTIVELY REDUCING PROCHIRAL KETONE TO ENANTIOMERICALLY PURE ALCOHOL BY REACTING SAID KETONE WITH BORANE REDUCING AGENT USING OXAZABOROLIDINE CATALYST | PFIZER INC. (US) | 1999-12-21 | — | — | US | disclosed |
| EP-0698028-B1 | ENANTIOSELECTIVE OXAZABOROLIDINE CATALYSTS | PFIZER (US) | 1997-02-26 | — | — | EP | disclosed |
| EP-0640089-B1 | ENANTIOSELECTIVE OXAZABOROLIDINE CATALYSTS | PFIZER (US) | 1996-12-27 | — | — | EP | disclosed |
| US-5552548-A | Enantioselective oxazaborolidine catalysts | PFIZER INC. (US) | 1996-09-03 | — | — | US | disclosed |
| CN-1124962-A | Enantioselective oxazaborolidine catalysts | PFIZER (US) | 1996-06-19 | — | — | CN | disclosed |
| EP-0698028-A1 | ENANTIOSELECTIVE OXAZABOROLIDINE CATALYSTS | PFIZER (US) | 1996-02-28 | — | — | EP | disclosed |
| EP-0640089-A1 | ENANTIOSELECTIVE OXAZABOROLIDINE CATALYSTS. | PFIZER (US) | 1995-03-01 | — | — | EP | disclosed |
| WO-1994026751-A1 | ENANTIOSELECTIVE OXAZABOROLIDINE CATALYSTS | PFIZER INC. (US) | 1994-11-24 | — | — | WO | disclosed |
| WO-1993023408-A1 | ENANTIOSELECTIVE OXAZABOROLIDINE CATALYSTS | PFIZER INC. (US) | 1993-11-25 | — | — | WO | disclosed |
| US-4497960-A | Chiral, optically active compounds useful as protective groups for hydroxy, thiol and amino compounds | NOE CHRISTIAN (AT) | 1985-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SCN2A, HTR2A, HTR2C | IDO1 724/4885TSHR 2163/4885BLM 2269/4885 |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SCN2A, HTR2A, HTR2C | IDO1 724/4885TSHR 2163/4885BLM 2269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.